Apogee Therapeutics (APGE) Projected to Post Earnings on Monday

Apogee Therapeutics (NASDAQ:APGE) is projected to release its Q4 2025 results before the market opens on Monday, March 2nd. Analysts expect Apogee Therapeutics to announce earnings of ($1.05) per share for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Wednesday, March 4, 2026 at 4:00 PM ET.

Apogee Therapeutics Stock Performance

APGE opened at $70.00 on Friday. The company has a market capitalization of $4.78 billion, a PE ratio of -15.98 and a beta of 1.42. The stock’s fifty day moving average is $73.04 and its 200-day moving average is $59.49. Apogee Therapeutics has a one year low of $26.20 and a one year high of $84.56.

Wall Street Analysts Forecast Growth

APGE has been the subject of a number of research analyst reports. UBS Group raised shares of Apogee Therapeutics to a “strong-buy” rating in a report on Wednesday, January 7th. Wall Street Zen cut Apogee Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, December 6th. Citigroup reaffirmed a “buy” rating on shares of Apogee Therapeutics in a research report on Sunday, January 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Apogee Therapeutics in a research note on Wednesday, January 21st. Finally, BTIG Research set a $137.00 target price on Apogee Therapeutics in a report on Tuesday, January 6th. Three investment analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $104.58.

Insider Activity at Apogee Therapeutics

In related news, insider Carl Dambkowski sold 5,500 shares of the company’s stock in a transaction on Wednesday, February 4th. The shares were sold at an average price of $65.79, for a total value of $361,845.00. Following the completion of the sale, the insider directly owned 211,148 shares in the company, valued at approximately $13,891,426.92. This represents a 2.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Michael Thomas Henderson sold 20,000 shares of the stock in a transaction on Wednesday, February 11th. The stock was sold at an average price of $63.35, for a total transaction of $1,267,000.00. Following the transaction, the chief executive officer directly owned 1,172,987 shares in the company, valued at $74,308,726.45. The trade was a 1.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 1,885,100 shares of company stock valued at $143,557,153. Insiders own 42.77% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in APGE. Los Angeles Capital Management LLC acquired a new position in Apogee Therapeutics during the fourth quarter valued at approximately $37,000. Quantbot Technologies LP bought a new stake in shares of Apogee Therapeutics during the 3rd quarter worth $96,000. BNP Paribas Financial Markets boosted its holdings in shares of Apogee Therapeutics by 34.7% during the 2nd quarter. BNP Paribas Financial Markets now owns 3,649 shares of the company’s stock worth $158,000 after buying an additional 941 shares during the period. Ensign Peak Advisors Inc acquired a new position in Apogee Therapeutics in the 4th quarter valued at $170,000. Finally, Quarry LP bought a new position in Apogee Therapeutics in the 4th quarter worth $189,000. 79.04% of the stock is owned by institutional investors.

About Apogee Therapeutics

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.